UNSPSC 51262609: Phentolamine mesilate or mesylate

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H19N3O.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7543E5K9T, chemically known as m-(n-(2-imidazolin-2-ylmethyl)-p-toluidino)phenol monomethanesulfonate (salt), but more generally known as phentolamine mesylate, which bears US NIH Compound Identifier 5775. European Medicines Agency schedules phentolamine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09785MIG.

UNSPSC 51262609 Phentolamine mesilate or mesylate is a Commodity code that in recent state and local procurement activity covers emergency-response pharmaceuticals and related drug-management systems procured for public health and safety programs. State and local buying under this code spans county health departments and state health agencies acquiring naloxone (opioid antagonist), drug deactivation systems, and related pharmaceutical products to support community health initiatives and emergency response capabilities. The issuing bodies include county-level public health authorities and state health and human services commissions, with procurement structures ranging from competitive sealed bids for near-term supply needs to exploratory requests for information gathering on direct-to-manufacturer pharmacy contracting models.

Recent activity appears concentrated in Florida and Texas. Seminole County, Florida posted an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with response due July 26, 2023, at 2:00 pm; the contract included an initial two-year term with a one-year renewal option and required drug-free workplace certification, E-Verify compliance, and specific insurance coverage. The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on April 3, 2026, to solicit vendor capabilities and market intelligence on direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives, functioning as a preliminary information-gathering phase prior to formal competitive solicitation. Neither opportunity specified explicit dollar values or disadvantaged-enterprise set-asides.